IR FAQs

Q&A：検索

Q&A：表示(英)

1What is the features of KWB among the bio-related companies?: KWB promotes a development of bio medicine products without having manufacturing facilities.
From the early stage, we have focused on the future potential of biosimilar product and realized G-CSF (Filgrastim BS).
For further details, please refer to the "Features /Strength"

2What are the differences between new bio medicine and biosimilars?: For the differences between new bio medicine and biosimilars, please refer to the following "Bio Medicine Products and the Market".

Bio medicine products are medicines originating from biological processes, and the pharmacological effects that can not be achieved with existing small molecule drugs are attracting attention.
According to the report issued by METI (Ministry of Economy, Trade and Industry in Japan), the market for bio medicine products has reached more than $ 75 billion in 2007 and accounted for more than 10% of the world's pharmaceuticals market in 2007. Among the top 10 products in the global drug sales market, the number of bio medicine product from only 1 in 2000 to four in 2007. In addition, 22 bio medicine products account for over $ 1 billion in sales. "(Source: Report by Ministry of Economy, Trade and Industry (June, 2010)) . Biosimilar is a product with the same or similar quality as new bio medicine products, which have already been approved for marketing. The new bio medicine products will reach the timing of patent expiration, biosimilar is expected to form a large market globally in the future.

1Where can I obtain the latest financial report?: Please refer to the latest financial result in "IR Information"

2How can I obtain the information about latest financial status?: Please refer to the latest financial result in "IR Information"

3How can I obtain the latest financial forecast?: Please refer to the latest financial forecast in "Topics"

4When is the next financial result to be reported?: Please refer to the "IR Calendar"

Our Goal